TScan Therapeutics (TCRX)
(Delayed Data from NSDQ)
$5.71 USD
-0.15 (-2.56%)
Updated Jul 5, 2024 04:00 PM ET
After-Market: $5.69 -0.02 (-0.35%) 5:32 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
TScan Therapeutics, Inc. (TCRX) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$11.86 | $15.00 | $9.00 | 106.98% |
Price Target
Based on short-term price targets offered by seven analysts, the average price target for TScan Therapeutics, Inc. comes to $11.86. The forecasts range from a low of $9.00 to a high of $15.00. The average price target represents an increase of 106.98% from the last closing price of $5.73.
Analyst Price Targets (7 )
Broker Rating
TScan Therapeutics, Inc. currently has an average brokerage recommendation (ABR) of 1.13 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by eight brokerage firms. The current ABR compares to an ABR of 1.13 a month ago based on eight recommendations.
Of the eight recommendations deriving the current ABR, seven are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 87.5% and 12.5% of all recommendations. A month ago, Strong Buy made up 87.5%, while Buy represented 12.5%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/TCRX.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 7 | 7 | 7 | 6 | 6 |
Buy | 1 | 1 | 1 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.13 | 1.13 | 1.13 | 1.00 | 1.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
5/16/2024 | BTIG | Justin R Zelin | Not Available | Strong Buy |
5/13/2024 | Needham & Company | Gil J Blum | Not Available | Moderate Buy |
4/1/2024 | Cowen & Co. | Tara Bancroft | Strong Buy | Strong Buy |
3/7/2024 | H.C. Wainwright & Co. | Andrew S Fein | Strong Buy | Strong Buy |
3/7/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
3/6/2024 | Wedbush Securities | David M Nierengarten | Strong Buy | Strong Buy |
2/27/2024 | LifeSci Capital | Sam Slutsky | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.13 |
ABR (Last week) | 1.13 |
# of Recs in ABR | 8 |
Average Target Price | $11.86 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 82 of 252 |
Current Quarter EPS Est: | -0.30 |